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Abstract
Although statins impart a number of cardiovascular benefits, whether statin therapy during the peri-infarct period improves
subsequent myocardial structure and function remains unclear. Thus, we evaluated the effects of atorvastatin on cardiac
function, remodeling, fibrosis, and apoptosis after myocardial infarction (MI). Two groups of rats were subjected to
permanent coronary occlusion. Group II (n=14) received oral atorvastatin (10 mg/kg/d) daily for 3 wk before and 4 wk after
MI, while group I (n=12) received equivalent doses of vehicle. Infarct size (Masson’s trichrome-stained sections) was similar
in both groups. Compared with group I, echocardiographic left ventricular ejection fraction (LVEF) and fractional area
change (FAC) were higher while LV end-diastolic volume (LVEDV) and LV end-systolic and end-diastolic diameters (LVESD
and LVEDD) were lower in treated rats. Hemodynamically, atorvastatin-treated rats exhibited significantly higher dP/dtmax,
end-systolic elastance (Ees), and preload recruitable stroke work (PRSW) and lower LV end-diastolic pressure (LVEDP).
Morphometrically, infarct wall thickness was greater in treated rats. The improvement of LV function by atorvastatin was
associated with a decrease in hydroxyproline content and in the number of apoptotic cardiomyocyte nuclei. We conclude
that atorvastatin therapy during the peri-infarct period significantly improves LV function and limits adverse LV remodeling
following MI independent of a reduction in infarct size. These salubrious effects may be due in part to a decrease in
myocardial fibrosis and apoptosis.
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Introduction
Myocardial infarction (MI) frequently causes left ventricular
(LV) dilatation associated with myocyte hypertrophy and intersti-
tial fibrosis of the noninfarcted myocardium. These changes in LV
geometry, referred to as remodeling, contribute to the develop-
ment of depressed cardiac performance [1]. Ventricular remod-
eling is further characterized by cardiac fibroblast proliferation
and apoptotic cell death [2]. These pathological processes can lead
to cardiac fibrosis as a result of disproportionate accumulation of
extracellular matrix components, which impedes both contraction
and relaxation and is arrhythmogenic [2,3,4]. Although available
therapies delay the progressive downward course of heart failure,
the prognosis of this syndrome remains bleak [5,6]. Therefore, it is
of critical importance to develop therapeutic strategies that will
effectively inhibit the development and progression of LV
remodeling and failure after MI.
The 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA)
reductase inhibitors, statins, lower plasma cholesterol levels and
have been associated with reduced morbidity and mortality in
patients with coronary artery disease [7,8]. It is presumed that
statins may cause regression or stabilization of atherosclerotic
plaques by lowering serum cholesterol levels [9]. However, the
beneficial effects of statins on coronary artery disease are not
limited to their ability to lower plasma cholesterol [7], but involve
various pleiotropic effects on atherosclerosis including reduction of
plaque thrombogenicity, inhibition of cellular proliferation and
migration, anti-inflammatory effects, and improvement of endo-
thelial function [10]. Despite the widespread clinical use of statins
for hypercholesterolemia and prevention of coronary artery
disease, data are lacking on the effects of statins on clinical
outcome in heart failure secondary to MI. Although some clinical
trials suggest that statins may attenuate remodeling and inflam-
mation in patients with cardiomyopathy [11,12], a recent
randomized placebo-controlled study of high-dose statin in
patients with systolic heart failure has shown no effect on
ventricular remodeling [13]. Thus, the role of statins in heart
failure due to MI remains controversial. Therefore, the purpose
of this study was to determine whether administration of a
statin during the peri-infarct period attenuates the progressive
LV chamber dilatation and contractile dysfunction in a rat model
of MI.
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Ethics Statement
All studies were performed in accordance with the guidelines of
the Animal Care and Use Committee of the University of
Louisville (Ky) School of Medicine and with the Guide for the Care
and Use of Laboratory Animals (Department of Health and Human
Services, Publication No. [NIH] 86-23). The animal experiments
were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Louisville (# 08137).
Treatment and surgical protocols
Female Fischer 344 rats (age 10–12 wk; body wt, 175–200 g,
Harlan Sprague-Dawley, Inc.) received oral atorvastatin (10 mg/
kg/d by gavage, group II, n=20) or an equivalent volume of
vehicle (water, group I, n=20) daily for 7 weeks starting 3 weeks
before and continuing for 4 weeks after MI. To adjust the daily
dose of the drug, the body weight was measured twice a week. The
dose of atorvastatin used in this study is considered safe [14] and is
similar to previously used doses shown to have cardioprotective
effects in terms of limiting infarct size in rats [15],[16]. As statin
use has been reported to have cardioprotective effects in patients
when initiated prior to the onset of MI [17] and in the first few
weeks after MI [18], we chose to treat the animals before and after
the onset of MI to mimic the common clinical situation in which
patients are treated with statins chronically, i.e., during the entire
peri-infarct period. Three weeks into the treatment, rats were
anesthetized with ketamine (37 mg/kg) and xylazine (5 mg/kg),
intubated, and ventilated with a rodent respirator (Harvard
Apparatus). Under sterile conditions, a left thoracotomy was
performed in the fourth intercostal space, and a 5-0 Prolene suture
tied around the left anterior descending coronary artery at 2–3
millimeters from its origin. The chest was closed with a 3-0 silk
suture. The animals continued to receive the assigned treatment
and were euthanized at 4 weeks after coronary artery ligation.
Echocardiography
Serial echocardiographic studies were performed 4 days before
surgery (baseline, BSL) and at 48 h and 4 wk after infarction
under light anesthesia (pentobarbital, 25 mg/kg, i.p.) [19]. The
anterior chest was shaved and rats were placed in the left lateral
decubitus position. Body temperature was maintained between
36.9uC and 37.3uC. Echocardiographic images were obtained
using a Philips HDI 5000 SonoCT ultrasound system equipped
with a 12-5 MHz phased-array probe fitted with a 0.3 cm standoff
and a 15-7 MHz broadband linear probe. The heart was imaged
in the para-sternal short axis view at the level of the papillary
muscles to obtain LV wall thickness and ejection fraction (EF), and
in the para-sternal long axis view to measure LV end-systolic and
end-diastolic volumes (LVESV and LVEDV). All measurements
were averaged in three consecutive cardiac cycles and analyzed
off-line by a single blinded observer using the ProSolv image
analysis software. All calculations were derived using standard
formulas. LV end-systolic and end-diastolic diameters (LVESD
and LVEDD) were measured from M-mode tracings obtained at
the mid-papillary level and analyzed according to modified
American Society for Echocardiography standards (posterior wall
leading-edge to leading-edge and anterior wall trailing-edge to
trailing-edge) [20].
Hemodynamics
Hemodynamic studies were performed at 4 wk after MI,
just before euthanasia. Rats were anesthetized with ketamine
(37 mg/kg) and xylazine (5 mg/kg), intubated, and mechanically
ventilated. Anesthesia was maintained with 1% isoflurane and the
core temperature kept at 37.0uC with a heating pad throughout
the study. A 2F microtip pressure-volume (PV) catheter (SPR-869,
Millar Instruments) was inserted into the right carotid artery and
advanced into the LV cavity. The right jugular vein was
cannulated for fluid administration. After 20 min of stabilization,
the PV signals were recorded continuously with an ARIA PV
conductance system (Millar Instruments) coupled with a Power-
lab/4SP A/D converter (AD Instruments), stored, and displayed
on a personal computer. PV relations were assessed by transiently
compressing the inferior vena cava with a cotton swab. Parallel
conductance from surrounding structures was calculated by
injecting a small bolus of 15% NaCl through the jugular vein.
LV end-diastolic pressure (LVEDP), dP/dtmax, end-systolic
elastance (Ees), and preload recruitable stroke work (PRSW) were
calculated using the PVAN software program (Millar) [21].
Morphometry and histology
After the hemodynamic measurements, a polyethylene catheter
filled with phosphate buffer (0.2 M, pH 7.4) and heparin (100 IU/
ml) was advanced to the ascending aorta via the right carotid
artery. In rapid succession, the heart was arrested in diastole by
injecting 1.0 ml of a mixture of cadmium chloride (100 mM)/
potassium chloride (3 M) through the aortic catheter. The heart
was then excised and perfused retrogradely with phosphate buffer
for ,3 min to flush out residual blood in the coronary circulation,
followed by perfusion with 10% neutral buffered formalin solution
for 15 min. Perfusion pressure was maintained between 60 and
80 mmHg while end-diastolic pressure was kept at 8 mmHg. After
perfusion-fixation, the atria and right ventricle were dissected from
the left ventricle. The LV weight was measured. The heart was cut
into four transverse slices (,2-mm thick), which were processed,
embedded in paraffin, sectioned at 4-mm intervals, and stained
with Masson’s trichrome. Images were acquired digitally and
analyzed using NIH ImageJ (1.37v). From the Masson’s
trichrome-stained images, morphometric parameters including
LV chamber diameter and infarct wall thickness were measured in
each section. All anatomical parameters were corrected according
to a uniform sarcomere length [22].
Myocardial hydroxyproline content assay
Hydroxyproline was assayed using a procedure described
previously [23]. The apex of the left ventricle was lysed. The
sample was centrifuged at 4,000 rpm for 10 min. The supernatant
was mixed with fresh chloramine T for 10 min and then with
Ehrlich’s reagent at 75uC for 20 min. After samples were cooled,
optical density was read at 560 nm with a spectrophotometer that
was adjusted by a blank. The blank was prepared by the same
procedure but without cardiac tissues in the reaction mixture.
Hydroxyproline concentration, expressed as mg/mg of wet heart
weight, was then calculated as previously described [23].
Detection of cardiomyocyte apoptosis
Apoptosis was determined in heart sections with in situ hairpin-
1 ligation (hairpin-1-biotin probe: 59-GCGCTAGACCT*GGTC-
TAGCGCA-39; T* represents biotinylated deoxythymidine [dT])
[24]. Briefly, fixed sections (4-mm) were first digested with
Proteinase K (25 mg/ml) for 15 min, then incubated with 50 ml
of T4 ligation buffer (T4 DNA ligase, 1 mM EDTA, 15%
polyethylene glycol) and a biotin labeled hairpin-1 probe for 16 h,
and then incubated with streptavidin-conjugated Texas-Red. A
total of 2,000 cardiomyocyte nuclei were counted in each section
after co-staining with hairpin-1.
Statins and Ventricular Remodeling
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25320Statistical analysis
Data are reported as mean6SEM. Measurements were
analyzed by ANOVA followed by unpaired Student t-tests with
the Bonferroni correction. A value of P,0.05 was considered
statistically significant. All statistical analyses were performed using
the SPSS software (version 8, SPSS, Inc., Chicago, IL).
Results
A total of 40 rats (20 in each group) were initially enrolled in the
study. Eight rats in the vehicle-treated group (group I) and 6 in the
atorvastatin-treated group (group II) died within the first 24 h after
coronary ligation due to ventricular fibrillation. An additional 5
rats died after the initial 24 h during the 4-wk follow-up period (3
in the vehicle-treated and 2 in the atorvastatin-treated group), so
that a total of 9 and 12 rats completed the protocol in groups I and
II, respectively. There were no significant differences in mortality,
body weight, heart weight, and heart/body weight ratio between
the two groups of rats.
Myocardial infarct size
The infarct area fraction (which measures the average area of
scarred tissue, expressed as a percent of the LV area in three LV
Figure 1. Myocardial infarct size. Myocardial infarct area fraction
assessed from Masson’s trichrome-stained hearts in vehicle-treated, and
atorvastatin-treated rats 4 wk after coronary occlusion. #, Individual
rats;N, mean6SEM.
doi:10.1371/journal.pone.0025320.g001
Figure 2. Echocardiographic assessment of LV function. Representative two-dimensional (A, C) and M-mode (B, D) images from vehicle-
treated (A, B), and atorvastatin-treated (C, D) rats 4 wk after coronary occlusion. The infarct wall is delineated by arrowheads. Compared with the
vehicle-treated heart, the atorvastatin-treated heart exhibited a smaller LV cavity, a thicker infarct wall, and improved motion of the infarct wall.
Contractile activity in the infarct area is present in the atorvastatin-treated heart and virtually absent in the vehicle-treated heart. Panels (E–J)
demonstrate that treatment with atorvastatin improved echocardiographic measurements of LV systolic function at 4 wk after myocardial infarction.
Data are mean 6 SEM. n=8–12 rats per group. *, P,0.05 versus vehicle-treated rats at 4 wk. BSL, baseline.
doi:10.1371/journal.pone.0025320.g002
Statins and Ventricular Remodeling
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25320sections 0.5–1.0 mm apart) was similar in atorvastatin- and
vehicle-treated rats (20.562.7% vs. 21.763.2%, respectively),
indicating that the extent of myocardial cell death produced by the
coronary ligation was comparable in both groups (Fig. 1).
Atorvastatin attenuates LV dysfunction
At baseline (4 days before surgery), all parameters of LV
function, measured by echocardiography, were similar in groups I
and II (Fig. 2). At 48 h after surgery, the degree of LV systolic
functional impairment did not differ among the groups (Figs. 2E–
2J), indicating that the extent of injury sustained during MI was
comparable. As expected, in vehicle-treated rats the infarct wall
thickness decreased (Figs. 2A, 2B and 2G) and the LVESD
increased at 4 wk of follow-up compared with baseline (Figs. 2A,
2B and 2H). In rats treated with atorvastatin, however, infarct wall
thickness was greater (Figs. 2C, 2D and 2G) and the LVESD
smaller (Figs. 2C, 2D and 2H) compared with vehicle-treated rats.
Vehicle-treated rats exhibited a progressive deterioration in LVEF
between 48 h and 4 wk after surgery; this worsening in LVEF was
attenuated in rats treated with atorvastatin, resulting in a markedly
greater LVEF at 4 wk compared with vehicle-treated rats
(34.1661.64% vs. 24.3063.39%; P,0.05; Fig. 2E). Furthermore,
LV systolic area was smaller and fractional area change was larger
in atorvastatin-treated rats compared with vehicle-treated rats
(Figs. 2I and 2J).
Consistent with the echocardiographic data, invasive assessment
of cardiac function using the conductance catheter showed
improved LV function in atorvastatin-treated animals. Fig. 3
shows representative P-V loops, dP/dtmax, LVEDP, end-systolic
elastance (Ees), and preload recruitable stroke work (PRSW)
obtained during IVC occlusion. Both load-dependent (LV dP/
dtmax, LVEDP) and load-independent (Ees, PRSW) parameters
of LV performance were improved in the atorvastatin-treated
group.
Figure 3. Hemodynamic assessment of LV function at 4 wk after atorvastatin treatment. Representative pressure-volume loops from a
vehicle-treated (A) and an atorvastatin-treated (B) rat recorded during preload manipulation by a brief period of inferior vena cava occlusion. Panels
C–F illustrate the quantitative analysis of hemodynamic variables including dP/dt (C), LV end-diastolic pressure (D), end-systolic elastance (E), and
preload recruitable stroke work (F). Data are mean 6 SEM. n=8–12 rats per group. *, P,0.05 versus vehicle-treated rats at 4 wk. Abbreviations: Ees,
end-systolic elastance; LVEDP, left ventricular end-diastolic pressure; PRSW, preload recruitable stroke work.
doi:10.1371/journal.pone.0025320.g003
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At 4 wk after MI, echocardiographic assessment showed an
increase in LVEDD, LV end-diastolic area, and LVEDV in
vehicle-treated rats, consistent with postinfarction LV remodeling
(Figs. 2A, 2B and 4B–4D). However, in atorvastatin-treated rats,
these variables were significantly smaller compared with vehicle-
treated rats, indicating improvement in LV remodeling (Figs. 2C,
2D and 4B–4D).
Morphometric analysis confirmed the echocardiographic find-
ings. Compared with the vehicle-treated group, the LV chamber
diameter was smaller and the infarct wall thickness and infarct wall
thickness/chamber diameter ratio were greater in the atorvastatin-
treated group (Fig. 5).
Atorvastatin reduces hydroxyproline content and
apoptotic cardiomyocytes
Because myocardial fibrosis contributes to the pathology of
ventricular remodeling [25,26], we examined whether atorvastatin
attenuated myocardial collagen content. As shown in Fig. 6, the
myocardial hydroxyproline content in the ischemic and nonisch-
emic zones was significantly higher in the vehicle-treated group
compared with the atorvastatin-treated group (0.1360.01 vs.
0.0960.02 and 0.1160.01 vs. 0.0560.01 mg/mg wet weight,
P,0.05, respectively). In addition, myocardial apoptotic nuclear
density (i.e., the percentage of nuclei that were apoptotic) was
significantly higher in vehicle-treated compared with atorvastatin-
treated hearts (ischemic zone: 2.3560.25% vs. 1.0660.24%;
Figure 4. Quantitative assessment of LV remodeling. Panels A–D illustrates echocardiographic measurement of LV AW thickness in
diastole (A), LV end-diastolic diameter (B), LV end-diastolic area (C) and LV end-diastolic volume (D) at baseline, 48 hr and 4 wk after
myocardial infarction. The administration of atorvastatin improved adverse LV remodeling at 4 wk after myocardial infarction. Data are mean 6
SEM. n=8–12 rats per group. *, P,0.05 versus vehicle-treated rats at 4 wk. Abbreviations: AW, anterior wall; BSL, baseline; hr, hours; LV, left
ventricular.
doi:10.1371/journal.pone.0025320.g004
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7B). Thus, atorvastatin treatment was associated with a lower
percentage of apoptotic nuclei in both the ischemic and the border
zones.
Discussion
The major finding of this study is that administration of
atorvastatin during the peri-infarct period improves LV function
and attenuates adverse LV remodeling after MI independent of a
reduction in infarct size. This salubrious effect was associated with
a decrease in myocardial fibrosis and in cardiomyocyte apoptosis.
Our observations of preserved LV function and mitigated LV
remodeling are consistent with previous studies of statins in acute
MI. In animal models of MI, cerivastatin (started on the 7
th day
after MI) [27] and fluvastatin (administered for 4 weeks after MI)
[28] have been reported to increase survival and improve cardiac
function along with an attenuation of LV remodeling. Further-
more, results from clinical studies in patients with idiopathic
dilated cardiomyopathy [29] and nonischemic forms of heart
failure [11,30] also suggest that statins may improve the clinical
status of patients by improving LV function and attenuating
adverse remodeling in heart failure. Similarly, statin therapy has
been shown to reduce the extent of periprocedural non-Q-wave
MI [31], microembolization and microinfarction [32] when
started before percutaneous coronary intervention.
The precise mechanism(s) whereby atorvastatin improved LV
function is unclear. The drug did not reduce infarct size (Fig. 1). In
contrast, previous studies of statins in animal models of ischemia-
reperfusion injury have shown reduction of infarct size and
limitation of infarct expansion due to salvage of jeopardized
myocardium [33,34,35]. The lack of early reperfusion in our
experimental model is likely to account for the lack of effect of
atorvastatin on infarct size, since salvage of ischemic myocardium
is not possible when the coronary occlusion is permanent [36]. It is
Figure 5. Morphometric assessment of LV remodeling. Repre-
sentative Masson’s trichrome-stained myocardial sections from vehicle-
treated (A) and atorvastatin-treated (B) hearts. Scar tissue and viable
myocardium are identified in white and red, respectively. Note that the
LV cavity is smaller and the infarct wall thicker in the atorvastatin-
treated heart. Panels (C, D) illustrate morphometric measurements of LV
structural parameters. Data are mean 6 SEM. n=8–12 rats per group.
*, P,0.05 versus vehicle-treated rats at 4 wk.
doi:10.1371/journal.pone.0025320.g005
Figure 6. Myocardial collagen content. Panels A–B shows the
quantitative assessment of collagen content in the ischemic zone (A)
and non-ischemic zone (B) at 4 wk after myocardial infarction. The
administration of atorvastatin decreased the collagen content at 4 wk
after myocardial infarction. Data are mean 6 SEM. n=8–12 rats per
group. *, P,0.05 versus vehicle-treated rats at 4 wk.
doi:10.1371/journal.pone.0025320.g006
Figure 7. Quantitative assessment of apoptotic cardiomyocyte
nuclei following in-situ ligation of hairpin oligonucleotides at
4 wk after myocardial infarction. Panels A and B show the
quantitative assessment of apoptotic cardiomyocyte nuclei in the
ischemic zone (A) and border zone (B). The administration of
atorvastatin decreased the number of apoptotic nuclei at 4 wk after
myocardial infarction. Hp+, hairpin positive. Data are mean 6 SEM.
n=8–12 rats per group. *, P,0.05 versus vehicle-treated rats at 4 wk.
The number of apoptotic cardiomyocytes was expressed as percent of
total number of cardiomyocytes.
doi:10.1371/journal.pone.0025320.g007
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apoptosis (Fig. 7) in the surviving myocardium resulted in less
fibrosis and greater preservation of contractile elements, thereby
contributing to the alleviation of LV dysfunction. It is unlikely that
changes in loading conditions could account for the salubrious
effects of atorvastatin because this drug has been reported to have
negligible effects on arterial pressure and heart rate [14]. Among
the many actions of statins that could contribute to the
improvement of LV function and structure after MI are enhanced
nitric oxide formation [37], inhibition of inflammation [38], and
normalization of augmented sympathetic outflow [39]. In
addition, by maintaining intracellular calcium homeostasis,
atorvastatin might modulate the expression of sarcoplasmic
reticulum calcium handling proteins and improve myocardial
function [40].
The finding that atorvastatin therapy led to a substantial
reduction of myocardial collagen content is novel. Although
reduction in collagen content by atorvastatin has been demon-
strated in animal models of diabetic cardiomyopathy [41] and in
spontaneously hypertensive rats [42], such an effect of the drug has
not been previously reported in the setting of MI. The end-
diastolic pressure-volume relationship, which indicates diastolic
stiffness, was improved by atorvastatin treatment. Unlike LVEDP,
which is load dependent, diastolic stiffness is independent of load.
Passive stiffness is a passive viscoelastic property that returns the
myocardium to its resting state [43]. An increase in passive stiffness
can be caused by abnormalities in cardiomyocytes, extracellular
matrix, or both [44]. Our finding that LV fibrosis was decreased in
the atorvastatin-treated group offers a plausible explanation for the
decreased diastolic stiffness in these animals. Myocardial fibrosis (a
major feature of LV remodeling after MI) is driven by angiotensin
II [45,46]. Since statins have been shown to prevent angiotensin
II-induced hypertrophy in cultured neonatal rat cardiac myocytes
(probably by attenuating angiotensin II-stimulated p21 ras activity
[47]), it is conceivable that angiotensin II antagonism was an
important mechanism whereby atorvastatin improved diastolic
stiffness.
Hairpin positivity reflects DNA break points, characteristic of
apoptosis [48]. The number of hairpin positive myocytes was
lower in atorvastatin-treated compared with vehicle-treated hearts
(Fig. 7). Whether this antiapoptotic effect of statins was due to
direct protective actions or was secondary to improved LV
function cannot be resolved from the present data.
Our data have obvious translational implications. They suggest
that the use of atorvastatin during the peri-infarct period might be
useful for limiting adverse LV remodeling and improving LV
function after MI. This approach might have a potential use in
clinical settings such as cardioprotection before surgical proce-
dures, including cardiac and major non-cardiac vascular surgery,
and patients with acute coronary syndromes. The exact mecha-
nism(s) of this protective effect, the minimal effective dose, and the
minimal duration of treatment required to achieve a beneficial
effect need further elucidation.
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